Pediatric acute myeloid leukemia - novel approaches

Area of Science:

• Pediatric Hematology-Oncology
• Cancer Therapeutics
• Leukemia Research

Background:

• Children with acute myeloid leukemia (AML) face high rates of treatment failure and late toxicities, despite better remission and survival rates than adults.
• Current treatment strategies require improvement to enhance long-term outcomes for pediatric AML patients.

Approach:

• This review highlights recent therapeutic advances in pediatric acute myeloid leukemia.
• It contextualizes these developments within the evolving landscape of cancer treatment.

Key Points:

• Novel agents, including B-cell lymphoma 2 inhibitors (e.g., venetoclax) and menin inhibitors, show promise for pediatric AML.
• Established agents are being repurposed in novel combinations (e.g., gemtuzumab ozogamicin) or adapted for pediatric use (e.g., Fms-like tyrosine kinase 3 inhibitors).
• Cellular and immunotherapeutic approaches provide new options for high-risk or relapsed pediatric AML cases.

Conclusions:

• Recent findings are significantly altering the therapeutic landscape for pediatric AML.
• These advances hold immediate and long-term implications for improving patient outcomes.